Linked Life Data

19483738

Source:http://linkedlifedata.com/resource/pubmed/id/19483738

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-6-1
pubmed:abstractText
From the original concepts that tumors require a vascular supply to grow and that blocking angiogenesis could suppress tumor growth, the oncology field has witnessed clinical successes of VEGF-targeted antiangiogenic medicine. The field is now facing the challenge of overcoming resistance to VEGF-targeted therapy, and therefore additional angiogenesis inhibitors are being developed. Studies on how endothelial 'tip, stalk and phalanx cells' form sprouts have identified promising candidate targets with complementary mechanisms to VEGF. This Review provides a conceptual framework in which molecular discoveries and principles are discussed in light of clinical opportunities to develop new antiangiogenic agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1759-4782
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
315-26
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.
pubmed:affiliation
Vesalius Research Center, VIB, KULeuven, Campus Gasthuisberg, Herestraat 49, Leuven, Belgium. peter.carmeliet@med.kuleuven.be
pubmed:publicationType
Journal Article, Review